Clinical Response to Rhinovirus Challenge

Exclusion criteria

• ✕. Positive test for serum neutralizing antibody to RV16 at enrollment visit (≥1:8) (Visit 1).
• ✕. Upper airway modified Jackson criteria symptom scores ≥7 at time of inoculation.
• ✕. Chronic heart disease including bradycardia, lung diseases other than asthma, or other chronic illnesses including epilepsy, peptic ulcer disease, thyroid disease, urinary tract infection, vagotonia, autoimmune disease, primary or secondary immunodeficiency or any household contacts who are known to be immune deficient. Any medical conditions that could be adversely affected by the administration of cholinergic agent.
• ✕. Any use of corticosteroids, leukotriene (LT) modifiers, antihistamines, omalizumab, theophylline, long-acting anti-muscarinic antagonists (LAMAs), long-acting beta-agonists (LABAs), nedocromil, cromolyn use on a daily basis within 4 weeks prior to Visit 1.
• ✕. Current use of ß-blockers or cholinesterase inhibitors (for myasthenia gravis).
• ✕. ß2-agonist use ≥4 days/week in any week or ≥2 nights/month during the month before Visit 1.
• ✕. Recent (within 1-yr) asthma exacerbation requiring urgent care visit (unless the treatment involved only the use of a bronchodilator), hospitalization, or oral CCS
• ✕. Intubation or management in the intensive care unit (ICU) for an asthma exacerbation ever.